SBL
ALBO

Sargent Bickham Lagudis’s Albireo Pharma Inc ALBO Stock Holding History

Sargent Bickham Lagudis’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$6.48K Hold
300
– – ﹤0.01% 777
2022
Q3 		$6K Buy
+300
New +$6.2K ﹤0.01% 772

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Sargent Bickham Lagudis's ALBO Position: Q4 2022 in Review

Sargent Bickham Lagudis held its Albireo Pharma Inc (ALBO) position steady in Q4 2022 at 300 shares worth $6.48K. The position accounts for ﹤0.01% of the portfolio, ranked #777.

Sargent Bickham Lagudis first reported a position in ALBO in Q3 2022 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold ALBO as of Q4 2022.

  • Sargent Bickham Lagudis held 300 shares of Albireo Pharma Inc worth $6.48K as of Q4 2022.
  • Sargent Bickham Lagudis left its Albireo Pharma Inc share count unchanged in Q4 2022.
  • Albireo Pharma Inc made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #777 holding.
  • Sargent Bickham Lagudis first reported a position in Albireo Pharma Inc in Q3 2022 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.